Gopi Shankar, Ph.D., MBA, FAAPS

Gopi Shankar, Ph.D., MBA, FAAPS

Chief Development OfficeratLarimar Therapeutics· In proxies 2022–2025

Pay in FY2024-16% from the year before · Larimar Therapeutics stock -14.9% the same year

Gopi Shankar, Ph.D., MBA, FAAPS was paid $1.2M in FY2024 (Dec), down 16%. Larimar Therapeutics stock fell 14.9% that year.

Pay$100 in the stock at the end of FY21 → $36
Pay is from the Summary Compensation Table of each Larimar Therapeutics proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Experience

  1. Larimar TherapeuticsPublic company · 4 yr
    • Chief Development Officer2022 – Present · 4 yrStock in role -75%

Roles come from the proxy statements of each company.

Activity

For the press:Download CSVDownload PNGHow to use our data

Two people shown as one, or a wrong number?